Journal Watch · Journal of Medicinal Chemistry · 2026
Design of Right-Handed D-Sulfonyl-γ-AApeptides with Broad-Spectrum Antimicrobial Activity.
Additionally, AM10 significantly reduced bacterial burden in a mice MRSA infection model, highlighting the sulfonyl-γ-AApeptide foldamers as a promising platform for the development of next-generation antimicrobial peptidomimetics.
TL;DR
Additionally, AM10 significantly reduced bacterial burden in a mice MRSA infection model, highlighting the sulfonyl-γ-AApeptide foldamers as a promising platform for the development of next-generation antimicrobial peptidomimetics.
Key findings
- The lead AApeptide AM10 demonstrated potent activity with rapid bactericidal kinetics, strong antibiofilm effects, minimal resistance development, and exceptional stability.
- Mechanistic studies revealed that AM10 exerts its effect through membrane perturbation and excessive reactive oxygen species (ROS) accumulation.
- Additionally, AM10 significantly reduced bacterial burden in a mice MRSA infection model, highlighting the sulfonyl-γ-AApeptide foldamers as a promising platform for the development of next-generation antimicrobial peptidomimetics.
What they did
However, the clinical applications of AMPs are hindered by their instability, cytotoxicity, and nonspecificity. Herein, we report a series of sulfonyl-γ-AApeptides helical foldamers, which exhibit broad-spectrum antibacterial activity and a high selectivity index against a panel of Gram-positive and -negative strains, including drug-resistant ones.
Full abstract (original)
Background: Antimicrobial resistance (AMR) has severely compromised the efficacy of conventional antibiotics, posing a major threat to global public health. Antimicrobial peptides (AMPs) emerged as a potential solution to combat multidrug-resistant pathogens.
What they did: However, the clinical applications of AMPs are hindered by their instability, cytotoxicity, and nonspecificity. Herein, we report a series of sulfonyl-γ-AApeptides helical foldamers, which exhibit broad-spectrum antibacterial activity and a high selectivity index against a panel of Gram-positive and -negative strains, including drug-resistant ones.
Results & conclusions: The lead AApeptide AM10 demonstrated potent activity with rapid bactericidal kinetics, strong antibiofilm effects, minimal resistance development, and exceptional stability. Mechanistic studies revealed that AM10 exerts its effect through membrane perturbation and excessive reactive oxygen species (ROS) accumulation. Additionally, AM10 significantly reduced bacterial burden in a mice MRSA infection model, highlighting the sulfonyl-γ-AApeptide foldamers as a promising platform for the development of next-generation antimicrobial peptidomimetics.
Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c00655 · PubMed 42377947.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Journal of Medicinal Chemistry for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Medicinal Chemistry study find?
Additionally, AM10 significantly reduced bacterial burden in a mice MRSA infection model, highlighting the sulfonyl-γ-AApeptide foldamers as a promising platform for the development of next-generation antimicrobial peptidomimetics.
What type of study is this?
It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. However, the clinical applications of AMPs are hindered by their instability, cytotoxicity, and nonspecificity.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acs.jmedchem.6c00655. PubMed ID: 42377947. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/design-of-right-handed-d-sulfonyl-aapeptides-with-broad-spectrum-antimic-c00655/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides